查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602811

抗生素市場：給藥途徑、按藥物類別、分銷管道 - 2025-2030 年全球預測

Antibacterial Drugs Market by Routes of Administration (Enteral, Parenteral), Drug Class (Aminoglycoside, B - Lactams, Macrolides), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗生素市值為376.3億美元，預計2024年將達到391.5億美元，複合年成長率為4.12%，到2030年將達到499.4億美元。

抗生素市場包括多種旨在對抗細菌感染的治療藥物。這些藥物在醫療保健和農業中發揮重要作用，可對抗從輕微到危及生命的各種疾病。細菌感染疾病的持續威脅強調了對抗菌劑的需求，而抗生素抗藥性菌株數量的增加加劇了這種威脅，特別是在治療肺炎、結核病和尿道感染的應用。最終使用領域主要包括醫院、診所和門診病人，但獸醫和農業也是重要的應用領域。促進市場成長的主要因素是感染疾病率的增加，以及人們對感染疾病認知的提高和診斷技術的進步。此外，細菌抗藥性模式的持續演變刺激了新藥類別的持續創新和研發工作，使得公司越來越渴望開發具有更好功效和安全性的新型抗菌劑，投資藥物和製劑開發的潛在機會正在擴大。然而，新興市場面臨重大限制，包括研發成本高、時間長、監管障礙以及限制新藥採用的潛在副作用。此外，現有抗生素的廣泛濫用和過度使用正在加劇抗藥性問題，並對產業成長構成挑戰。為了克服這些限制，需要在該領域進行創新，特別是在開發窄頻譜抗生素、噬菌體療法和益生菌等替代療法以及指導準確抗生素使用的快速診斷方面。公司還應專注於協作研究和夥伴關係關係，以縮短產品開發時間並提高市場滲透率。市場的動態性質需要不斷適應技術和監管變化，而進步和不斷發展的細菌抗藥性對於公司確保永續成長並為改善全球健康做出貢獻至關重要。

主要市場統計
基準年[2023] 376.3億美元
預測年份 [2024] 391.5億美元
預測年份 [2030] 499.4億美元
複合年成長率（%） 4.12%

市場動態：揭示快速發展的抗生素市場的關鍵市場洞察

供需的動態交互作用正在改變抗生素市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 感染疾病流行的蔓延
    • 新抗生素的核准和上市數量不斷增加
    • 學名藥的普及
  • 市場限制因素
    • 抗菌藥物專利到期
  • 市場機會
    • 開發具有更高功效和更少副作用的新化合物
    • 新興國家抗生素的採用
  • 市場挑戰
    • 多重抗藥性細菌的存在

波特五力：駕馭抗生素市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對抗菌藥物市場的影響

外部宏觀環境因素在塑造抗生素市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗菌藥物市場競爭狀況

抗生素市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗生素市場供應商的績效評估

FPNV定位矩陣是評估抗生素市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製抗生素市場的成功之路

抗生素市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病的傳播
      • 增加新抗生素的核准和上市
      • 學名藥的普及
    • 抑制因素
      • 抗菌藥物專利到期
    • 機會
      • 創新新化合物，提高療效並減少副作用
      • 新興國家抗生素的採用
    • 任務
      • 存在多重抗藥性菌株
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依給藥途徑分類的抗生素市場

  • 腸內的
  • 胃腸外的

第7章依藥物類別分類的抗生素市場

  • Aminoglycosides
  • B-內醯胺
  • 大環內酯
  • 苯尼考
  • 奎諾酮
  • 磺胺類藥物
  • 四環黴素

第8章抗生素市場：按分銷管道

  • 藥局和藥房
  • 醫院藥房
  • 網路藥房

第9章美洲抗生素市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區抗生素市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲抗生素市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Allecra Therapeutics GmbH
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Debiopharm Group
  • Eli Lilly and Company
  • Entasis Therapeutics by Innoviva, Inc.
  • GlaxoSmithKline PLC
  • Iterum Therapeutics PLC
  • Johnson & Johnson Services Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Melinta Therapeutics LLC
  • Merck & Co., Inc.
  • Sanofi-Aventis Groupe SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4358BACA8012

The Antibacterial Drugs Market was valued at USD 37.63 billion in 2023, expected to reach USD 39.15 billion in 2024, and is projected to grow at a CAGR of 4.12%, to USD 49.94 billion by 2030.

The market for antibacterial drugs encompasses a wide array of therapeutic agents designed to combat bacterial infections. These drugs play a critical role in both healthcare and agricultural sectors, countering diseases that range from mild to life-threatening. The necessity of antibacterial drugs is underscored by the persistent threat of bacterial infections, heightened by the rise of antibiotic-resistant strains, which significantly underscores their application in treating conditions such as pneumonia, tuberculosis, and urinary tract infections, among others. End-use sectors predominantly include hospitals, clinics, and outpatient facilities, while the veterinary industry and agriculture also represent significant application areas. A key influencer of market growth is the increasing prevalence of infectious diseases, coupled with heightened awareness and diagnostic advancements. Moreover, the constant evolution of bacterial resistance patterns stimulates ongoing innovation and R&D efforts into new drug classes, thus opening potential opportunities for companies to invest in the development of novel antibacterial agents or formulations with better efficacy and safety profiles. However, the market faces substantial limitations, notably the high costs and lengthy timelines associated with research and development, regulatory hurdles, and the potential for adverse effects, which restrict the proliferation of new drugs. Furthermore, the widespread misuse or overuse of existing antibiotics exacerbates resistance issues, posing a challenge to industry growth. To overcome these limitations, the sector is poised for innovation, especially in developing narrow-spectrum antibiotics, alternative therapies such as phage therapy and probiotics, and rapid diagnostics that guide precise antimicrobial use. Businesses should also focus on collaborations and partnerships to expedite product development timelines and enhance market penetration. The market's dynamic nature requires continuous adaptation to technological and regulatory changes, emphasizing the importance for companies to stay abreast of advancements and evolving bacterial resistance trends to secure sustained growth and contribute to global health improvements.

KEY MARKET STATISTICS
Base Year [2023] USD 37.63 billion
Estimated Year [2024] USD 39.15 billion
Forecast Year [2030] USD 49.94 billion
CAGR (%) 4.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibacterial Drugs Market

The Antibacterial Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of infectious diseases
    • Increasing approval and launch of new antibacterial drugs
    • Widespread of the generic drugs
  • Market Restraints
    • Patent expiry of the antibacterial drug
  • Market Opportunities
    • Innovation in some novel compounds with improved efficacy, and fewer side effects associated with the drugs
    • Adoption of antibacterial drugs in emerging countries
  • Market Challenges
    • Presence of multi-drug resistant bacterial strains

Porter's Five Forces: A Strategic Tool for Navigating the Antibacterial Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibacterial Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibacterial Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibacterial Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibacterial Drugs Market

A detailed market share analysis in the Antibacterial Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibacterial Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibacterial Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibacterial Drugs Market

A strategic analysis of the Antibacterial Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibacterial Drugs Market, highlighting leading vendors and their innovative profiles. These include Allecra Therapeutics GmbH, Allergan PLC, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Debiopharm Group, Eli Lilly and Company, Entasis Therapeutics by Innoviva, Inc., GlaxoSmithKline PLC, Iterum Therapeutics PLC, Johnson & Johnson Services Inc., Kyorin Pharmaceutical Co., Ltd., Melinta Therapeutics LLC, Merck & Co., Inc., Sanofi-Aventis Groupe S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibacterial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Routes of Administration, market is studied across Enteral and Parenteral.
  • Based on Drug Class, market is studied across Aminoglycoside, B - Lactams, Macrolides, Phenicols, Quinolones, Sulfonamide, and Tetracycline.
  • Based on Distribution Channel, market is studied across Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infectious diseases
      • 5.1.1.2. Increasing approval and launch of new antibacterial drugs
      • 5.1.1.3. Widespread of the generic drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiry of the antibacterial drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in some novel compounds with improved efficacy, and fewer side effects associated with the drugs
      • 5.1.3.2. Adoption of antibacterial drugs in emerging countries
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of multi-drug resistant bacterial strains
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibacterial Drugs Market, by Routes of Administration

  • 6.1. Introduction
  • 6.2. Enteral
  • 6.3. Parenteral

7. Antibacterial Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Aminoglycoside
  • 7.3. B - Lactams
  • 7.4. Macrolides
  • 7.5. Phenicols
  • 7.6. Quinolones
  • 7.7. Sulfonamide
  • 7.8. Tetracycline

8. Antibacterial Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores & Retail Pharmacies
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies

9. Americas Antibacterial Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibacterial Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibacterial Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allecra Therapeutics GmbH
  • 2. Allergan PLC
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb Company
  • 6. Debiopharm Group
  • 7. Eli Lilly and Company
  • 8. Entasis Therapeutics by Innoviva, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Iterum Therapeutics PLC
  • 11. Johnson & Johnson Services Inc.
  • 12. Kyorin Pharmaceutical Co., Ltd.
  • 13. Melinta Therapeutics LLC
  • 14. Merck & Co., Inc.
  • 15. Sanofi-Aventis Groupe S.A.
  • 16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIBACTERIAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBACTERIAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBACTERIAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY B - LACTAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PHENICOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG STORES & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023